Clinical Trial Update: Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis [Phase 2]

View source ↗

Summary

Phase 2 dose-response study evaluating paricalcitol injection in chronic kidney disease patients on hemodialysis with secondary hyperparathyroidism has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (paricalcitol) (paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Chronic Kidney Disease on Hemodialysis, Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED | Results posted: 2010-04-02